The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a huge mover today! The stock decreased 8.18% or $0.39 during the last trading session, hitting $4.38. About 2.33M shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has risen 3.70% since April 14, 2016 and is uptrending. It has underperformed by 0.99% the S&P500.
The move comes after 6 months negative chart setup for the $489.66M company. It was reported on Nov, 16 by Barchart.com. We have $3.81 PT which if reached, will make NASDAQ:CLDX worth $63.66M less.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage
Out of 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Celldex Therapeutics has been the topic of 16 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the shares of CLDX in a report on Monday, March 7 to “Market Perform” rating. H.C. Wainwright maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, March 8 with “Buy” rating. The rating was downgraded by Wedbush on Monday, March 7 to “Neutral”. TH Capital maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, August 11 with “Buy” rating. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Perform” rating given on Monday, March 7 by Oppenheimer. Cowen & Co maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating on Tuesday, March 8. Cowen & Co has “Outperform” rating and $12 price target. Jefferies downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, March 8 to “Hold” rating. The company was downgraded on Monday, March 7 by Guggenheim. The firm has “Buy” rating given on Tuesday, August 11 by Brean Capital. As per Tuesday, August 11, the company rating was maintained by Oppenheimer.
According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”
More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: Fool.com which released: “Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today” on November 14, 2016. Also Fool.com published the news titled: “Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc.” on October 18, 2016. Fool.com‘s news article titled: “Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.” with publication date: October 25, 2016 was also an interesting one.
CLDX Company Profile
Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.